In a report released on January 13, Brian Abrahams from RBC Capital maintained a Hold rating on BioCryst (BCRX – Research Report), with a price target of $12.00. The company’s shares closed last Friday at $10.16.
Abrahams covers the Healthcare sector, focusing on stocks such as Regeneron, Biogen, and Incyte. According to TipRanks, Abrahams has an average return of 7.7% and a 49.30% success rate on recommended stocks.
In addition to RBC Capital, BioCryst also received a Hold from Needham’s Serge Belanger in a report issued on January 9. However, on the same day, JMP Securities reiterated a Buy rating on BioCryst (NASDAQ: BCRX).
See today’s best-performing stocks on TipRanks >>
BCRX market cap is currently $1.89B and has a P/E ratio of -9.73.
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BCRX in relation to earlier this year. Last month, Jones Michael L, the Exec. Director, Finance – PAO of BCRX sold 8,600.00 shares for a total of $111,886.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
Read More on BCRX:
- BioCryst reports preliminary Q4 miss for Orladeyo, says Piper Sandler
- BioCryst reports initial clinical data on BCX10013
- BioCryst sees FY23 global net ORLADEYO revenue no less than $320M
- BioCryst sees Q4 ORLADEYO net revenue $70.7M
- BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance